KR20040108693A - 정제된 라소폭시펜 및 재결정화에 의한 라세미라소폭시펜의 정제 방법 - Google Patents
정제된 라소폭시펜 및 재결정화에 의한 라세미라소폭시펜의 정제 방법 Download PDFInfo
- Publication number
- KR20040108693A KR20040108693A KR10-2004-7015249A KR20047015249A KR20040108693A KR 20040108693 A KR20040108693 A KR 20040108693A KR 20047015249 A KR20047015249 A KR 20047015249A KR 20040108693 A KR20040108693 A KR 20040108693A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- ethanol
- racemic
- ylethoxy
- purified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Abstract
Description
Claims (12)
- (a) 에탄올 및 테트라하이드로푸란의 혼합물중에 라세미 시스-6-페닐-5-[4-(2-피롤리딘-l-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올을 현탁시켜 현탁액을 형성하는 단계;(b) 상기 단계 (a)에서 형성된 현탁액을 교반 및 가열하는 단계;(c) 상기 단계 (b)의 현탁액을 냉각하는 단계; 및(d) 고체의 정제된 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올을 수집하는 단계를 포함하는, 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올의 정제 방법.
- 제 1 항에 있어서,에탄올 및 테트라하이드로푸란의 혼합물이 4:1의 부피비를 갖는 방법.
- 제 1 항에 있어서,에탄올 및 테트라하이드로푸란의 혼합물이 3:1의 부피비를 갖는 방법.
- 제 1 항에 있어서,에탄올 및 테트라하이드로푸란의 혼합물이 2:1의 부피비를 갖는 방법.
- 제 1 항에 있어서,에탄올 및 테트라하이드로푸란의 혼합물이 1:1의 부피비를 갖는 방법.
- 제 1 항 내지 제 5 항중 어느 한 항에 있어서,단계 (a)에서 형성된 현탁액을 단계 (b)에서 교반하고 상온으로부터 70℃까지 가열하는 방법.
- 제 6 항에 있어서,단계 (a)에서 형성된 현탁액을 단계 (b)에서 교반하고 상온으로부터 65℃까지 12시간동안 가열하는 방법.
- 제 7 항에 있어서,단계 (b)에서 형성된 현탁액을 단계 (c)에서 18시간동안 냉각 및 교반하는 방법.
- 제 8 항에 있어서,단계 (c)에서 형성된 현탁액중의 고체의 정제된 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올을 불순물이 0.2% 미만의 되도록 여과하여 수집하는 방법.
- 제 8 항에 있어서,단계 (c)에서 형성된 현탁액중의 고체의 정제된 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올을 불순물이 0.1%미만이 되도록 여과하여 수집하는 방법.
- (a) 2:1의 부피비의 에탄올 및 테트라하이드로푸란의 혼합물중에 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올을 현탁시켜 현탁액을 형성하는 단계;(b) 상기 단계 (a)에서 형성된 현탁액을 교반하고 상온으로부터 65℃까지 12시간동안 가열하는 단계;(c) 형성된 현탁액을 18시간동안 교반하에 냉각하는 단계; 및(d) 여과에 의해 고체의 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올을 수집하는 단계를 포함하는, 라세미 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올의 정제 방법.
- 불순물이 0.1% 미만의 수준이 되도록 정제된 시스-6-페닐-5-[4-(2-피롤리딘-1-일에톡시)페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36887202P | 2002-03-28 | 2002-03-28 | |
US60/368,872 | 2002-03-28 | ||
PCT/IB2003/001033 WO2003082814A1 (en) | 2002-03-28 | 2003-03-17 | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040108693A true KR20040108693A (ko) | 2004-12-24 |
KR100636953B1 KR100636953B1 (ko) | 2006-10-19 |
Family
ID=28675551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047015249A KR100636953B1 (ko) | 2002-03-28 | 2003-03-17 | 정제된 라소폭시펜 및 재결정화에 의한 라세미라소폭시펜의 정제 방법 |
Country Status (23)
Country | Link |
---|---|
US (2) | US6906202B2 (ko) |
EP (1) | EP1487790B1 (ko) |
JP (1) | JP4268055B2 (ko) |
KR (1) | KR100636953B1 (ko) |
CN (1) | CN1283625C (ko) |
AR (1) | AR039152A1 (ko) |
AT (1) | ATE459599T1 (ko) |
AU (1) | AU2003209603B2 (ko) |
BR (1) | BR0308758A (ko) |
CA (1) | CA2479924C (ko) |
DE (1) | DE60331527D1 (ko) |
DK (1) | DK1487790T3 (ko) |
ES (1) | ES2339936T3 (ko) |
HK (1) | HK1073111A1 (ko) |
HU (1) | HUP0500025A3 (ko) |
IL (2) | IL162929A0 (ko) |
MX (1) | MXPA04009259A (ko) |
PL (1) | PL372727A1 (ko) |
RS (1) | RS80604A (ko) |
RU (1) | RU2278861C2 (ko) |
TW (1) | TW200306974A (ko) |
WO (1) | WO2003082814A1 (ko) |
ZA (1) | ZA200405209B (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0500025A3 (en) * | 2002-03-28 | 2005-10-28 | Pfizer Prod Inc | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
RU2019114079A (ru) | 2016-10-11 | 2020-11-13 | Дьюк Юниверсити | Лечение er+ рака молочной железы лазофоксифеном |
WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
KR102412089B1 (ko) | 2021-09-13 | 2022-06-22 | 주식회사 세라수 | Dmts의 정제방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326865A (en) * | 1990-06-08 | 1994-07-05 | Hercules Incorporated | Arylazo and poly(arylazo) dyes having at least one core radical selected from naphthyl or anthracyl and having at least one 2,3-dihydro-1,3-dialkyl perimidine substituent |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
EP0756205A3 (en) * | 1995-07-26 | 1998-10-14 | Eastman Kodak Company | Pattern transfer techniques for fabrication of lenslet arrays using specialized polyesters |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
US6180375B1 (en) | 1999-08-27 | 2001-01-30 | Pfizer Inc. | Microbial biotransformation |
CZ20032959A3 (cs) | 2001-05-01 | 2004-01-14 | Pfizer Products Inc. | Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva |
HUP0500025A3 (en) * | 2002-03-28 | 2005-10-28 | Pfizer Prod Inc | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
-
2003
- 2003-03-17 HU HU0500025A patent/HUP0500025A3/hu unknown
- 2003-03-17 WO PCT/IB2003/001033 patent/WO2003082814A1/en not_active Application Discontinuation
- 2003-03-17 DE DE60331527T patent/DE60331527D1/de not_active Expired - Lifetime
- 2003-03-17 RS YUP-806/04A patent/RS80604A/sr unknown
- 2003-03-17 BR BR0308758-1A patent/BR0308758A/pt not_active IP Right Cessation
- 2003-03-17 MX MXPA04009259A patent/MXPA04009259A/es active IP Right Grant
- 2003-03-17 RU RU2004128931/04A patent/RU2278861C2/ru not_active IP Right Cessation
- 2003-03-17 ES ES03745203T patent/ES2339936T3/es not_active Expired - Lifetime
- 2003-03-17 CA CA002479924A patent/CA2479924C/en not_active Expired - Fee Related
- 2003-03-17 JP JP2003580282A patent/JP4268055B2/ja not_active Expired - Fee Related
- 2003-03-17 IL IL16292903A patent/IL162929A0/xx unknown
- 2003-03-17 AU AU2003209603A patent/AU2003209603B2/en not_active Ceased
- 2003-03-17 EP EP03745203A patent/EP1487790B1/en not_active Expired - Lifetime
- 2003-03-17 DK DK03745203.4T patent/DK1487790T3/da active
- 2003-03-17 KR KR1020047015249A patent/KR100636953B1/ko active IP Right Grant
- 2003-03-17 AT AT03745203T patent/ATE459599T1/de not_active IP Right Cessation
- 2003-03-17 PL PL03372727A patent/PL372727A1/xx not_active Application Discontinuation
- 2003-03-17 CN CNB038031175A patent/CN1283625C/zh not_active Expired - Lifetime
- 2003-03-26 US US10/397,654 patent/US6906202B2/en not_active Expired - Lifetime
- 2003-03-26 AR ARP030101058A patent/AR039152A1/es unknown
- 2003-03-27 TW TW092106928A patent/TW200306974A/zh unknown
-
2004
- 2004-06-30 ZA ZA2004/05209A patent/ZA200405209B/en unknown
- 2004-07-08 IL IL162929A patent/IL162929A/en active IP Right Grant
-
2005
- 2005-03-28 US US11/092,240 patent/US7358374B2/en active Active
- 2005-07-11 HK HK05105808A patent/HK1073111A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5434304A (en) | Process for preparing formoterol and related compounds | |
EP0307303B1 (fr) | [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique | |
US7358374B2 (en) | Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a method for effective purification of racemic lasofoxifene | |
CZ44293A3 (en) | Novel process for preparing formoterol and related compounds | |
IE69017B1 (en) | Improved process for resolution of racemic cimaterol (-)-cimaterol and derivatives thereof | |
KR20170102204A (ko) | 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법 | |
ZA200604240B (en) | Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical purity | |
AU632844B2 (en) | Halogenoalkylphenyl-alcohols, -keytones and hydrates thereof | |
JP2002531429A (ja) | トラマドールの分割のための方法 | |
EP1149101B1 (fr) | Derives de 4-oxo-3,5-dihydro-4h-pyridazino [4,5-b] indole-1-carboxamide, leur preparation et leur application en therapeutique | |
EP0301936B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique | |
EP0532398A1 (fr) | Dérivés de N-(4,7-diméthoxyindan-2-yl)-1-(phénylcarbonyl)-N-propyl-pipéridine-4-méthanamine, leur préparation et leur application en thérapeutique | |
EP0916657B9 (en) | 1-phenylpyrrolidone derivatives having optical activity | |
SU1082318A3 (ru) | Способ выделени / @ /-1,2-дифенил-1-/ @ -/2-диметиламиноэтокси /-фенил/-бутена-1 или его солей | |
BE882361R (fr) | PROCEDE DE PREPARATION DE 10,11-DIHYDRO-5H-DIBENZO (a,d) CYCLOHEPTENE-5,10-IMINES SUBSTITUEES EN POSITION 5 | |
FR2494584A1 (fr) | Medicaments constitues par de nouveaux 2-aminoethanols et leur procede de fabrication | |
CN109280024A (zh) | 一种高纯度阿托伐他汀叔丁酯的制备方法 | |
WO2004078761A1 (en) | Enantiomerically pure cilazapril,process for preparation | |
CH315802A (fr) | Procédé de préparation d'un sel d'ammonium quaternaire | |
MXPA06007477A (en) | Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2- methoxybenzenesulphonamide hydrochloride of high chemical | |
ITMI20071657A1 (it) | Procedimento per la sintesi del nebivololo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120926 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130930 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141001 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 13 |